Ετικέτες

Πέμπτη 14 Φεβρουαρίου 2019

Evaluating Risks and Benefits of Evolving Systemic Treatments of Neuroendocrine Tumors

In recent years, the number of treatments for metastatic, well-differentiated gastrointestinal and pancreatic neuroendocrine tumors (NETs) has expanded significantly. New medications for tumor control as well as symptom control include somatostatin analogues, everolimus, sunitinib, telotristat, and lutetium Lu 177 (177Lu)-dotatate. These new therapies have been approved based on randomized clinical trials—an effort that has required international cooperation given the relative scarcity of metastatic NETs.

http://bit.ly/2tjZbXW

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αναζήτηση αυτού του ιστολογίου